Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you have a clinical oncology program or biotech platform validated for liquid biopsy or imaging biomarkers, this R01 funds prospective studies to prove integrated monitoring improves therapy guidance.
Report stale or inaccurate summary
What this is
This NIH R01 grant targets integrated clinical studies that use imaging (CT, MRI, PET, ultrasound) alongside fluid biomarkers (circulating tumor DNA, CTCs, proteins) to monitor cancer patients undergoing active therapy. The goal is to determine which combination of modalities best predicts treatment response and early resistance emergence. Applicants must propose patient cohorts, define clinical endpoints, and validate biomarker/imaging signatures. This is ideal for oncology researchers, clinical teams, or biotech companies with access to patient populations and the ability to conduct prospective clinical monitoring studies.
Who can apply
Broadly eligible: small businesses, nonprofits with or without 501(c)(3) status, universities, clinical research institutions, and state/local governments. Applicants must have or establish access to cancer patient cohorts undergoing active therapy and capacity to conduct clinical-grade monitoring and data collection. No geographic restrictions.
Eligible applicant types
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- City or township governments
- Small businesses
- For profit organizations other than small businesses
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Special district governments
- Independent school districts
- Native American tribal governments (Federally recognized)
- State governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- County governments
- Public housing authorities/Indian housing authorities
- Public and State controlled institutions of higher education
Full description — from the agency
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Topics: liquid biopsy cancer monitoring · imaging biomarkers oncology · treatment response assessment · circulating tumor DNA ctDNA · clinical trial cancer therapy · tumor resistance detection
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.